Allitinib tosylate
别名: AST-1306 TsOH, AST-6 中文名称：艾力替尼
Allitinib (AST-1306, AST-6) 是一种新型，不可逆的EGFR和ErbB2抑制剂，IC50分别为0.5 nM和3 nM，对突变型EGFR T790M/L858R也有效，作用于过表达ErbB2的细胞更有效，作用于ErbB家族比作用于其他激酶选择性高3000倍。
Allitinib tosylate Chemical Structure
CAS: 1050500-29-2
产品质控
Allitinib tosylate相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| NCI-H1975 cells | Proliferation assay | 72 h | Antiproliferative activity against human NCI-H1975 cells over-expressing EGFR mutant gene after 72 hrs by SRB assay, IC50=0.7 μM | 22227214 | |
| A431 cells | Proliferation assay | 72 h | Antiproliferative activity against human A431 cells over-expressing EGFR gene after 72 hrs by SRB assay, IC50=0.2 μM | 22227214 | |
| A549 cells | Proliferation assay | 72 h | Antiproliferative activity against human A549 cells over-expressing EGFR gene after 72 hrs by SRB assay, IC50=6.8 μM | 22227214 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Allitinib (AST-1306, AST-6) 是一种新型，不可逆的EGFR和ErbB2抑制剂，IC50分别为0.5 nM和3 nM，对突变型EGFR T790M/L858R也有效，作用于过表达ErbB2的细胞更有效，作用于ErbB家族比作用于其他激酶选择性高3000倍。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | AST-1306选择性抑制EGFR和ErbB2酪氨酸激酶活性。AST-1306也有效抑制T790M/L858R双突变型EGFR，IC50为12 nM。AST-1306效果比Lapatinib高500多倍。AST-1306作用于 ErbB 家族激酶比作用于其他激酶家族包括PDGFR, KDR和c-Met选择性高3000多倍。AST-1306 可能与EGFR和ErbB2氨基酸残基共价结合。AST-1306显著抑制HIH3T3-EGFR T790M/L858R 细胞生长，存在浓度依赖性。AST-1306作用于HIH3T3-EGFR T790M/L858R 细胞，有效抑制EGFR磷酸化。而且, AST-1306抑制含EGFR T790M/L858R 突变的NCI-H1975细胞生长，这种作用存在浓度依赖性。AST-1306抑制EGFR及其下游通路的磷酸化。此外, AST-1306作用于A549细胞,显著抑制EGF诱导的EGFR磷酸化，这种作用存在剂量依赖性。AST-1306作用于人癌细胞包括A549细胞, Calu-3细胞和SK-OV-3细胞，抑制EGFR和ErbB2及其下游信号磷酸化。 [1] | |||
|---|---|---|---|---|
| 激酶实验 | 酪氨酸激酶实验 | |||
| 在20 μg/mL 聚(Glu,Tyr)4:1预包被的96孔ELISA 板上测定酪氨酸激酶活性。首先, 每孔中加入在激酶反应buffer(50 mM HEPES pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2, 0.2 mM Na3VO4, 1 mM DTT) 中稀释的80 μL 5 μM ATP溶液。不同浓度AST-1306 在10 μL 1% DMSO (v/v) 中稀释，然后加到每孔中，对照组使用1% DMSO (v/v)。随后，加入在10 μL 激酶反应缓冲液中稀释的纯化酪氨酸激酶蛋白，开始激酶反应。 每种浓度的实验各进行重复实验。在37oC下温育60分钟后, 使用含0.1% Tween-20 (T-PBS)的PBS冲洗实验板三次。然后,加入在含5 mg/mL BSA的T-PBS中稀释的 100 μL磷酸酪氨酸抗体 (PY99, 按1:500稀释)。 在37oC下温育30分钟后,实验板再和之前一样冲洗三次。加入在含5 mg/mL BSA的 T-PBS中按1:2000稀释的辣根过氧化物酶标记的羊抗鼠IgG(100 μL)。然后实验板在37oC下预温育30分钟，然后使用 PBS冲洗。最后, 加入100 μL 含0.03 % H2O2和溶于0.1 M柠檬酸缓冲液（pH 5.5）的2 mg/mL o-对苯二胺的溶液，与样本在室温下温育，直到出现颜色。加入50 μL 2 M H2SO4终止反应,使用多孔分光光度计在 490 nm处读数。测定IC50值。 | ||||
| 细胞实验 | 细胞系 | Calu-3和A-549细胞系 | ||
| 浓度 | 0.001-1 μM | |||
| 孵育时间 | 72小时 | |||
| 方法 | 使用SRB(Sulforhodamine B)实验测定细胞(包括Calu-3, A-549细胞系等)增殖。细胞接种在96孔板上，培养24小时。使用浓度不断增长的AST-1306处理细胞72小时。维持培养基原样直到实验结束。细胞与10% 预冷的三氯乙酸(TCA)在 4oC下混合1小时，然后在室温下使用 100 μL溶于1%乙酸的 4 mg/mL SRB 溶液染色15分钟。移除SRB，然后使用1% 乙酸快速冲洗细胞5次。晾干细胞, 蛋白结合染料在 150 μL 10 mM Tris 碱中溶解5分钟，然后使用多孔分光光度计在515 nm 测量。测定IC50值。 | |||
| 体内研究(In Vivo) | ||
| 体内研究活性 | AST-1306每天口服处理SK-OV-3 和Calu-3移植瘤模型，显著抑制肿瘤生长。AST-1306处理SK-OV-3 模型，7天后，肿瘤几乎完全消失。相反, AST-1306 作用于HO-8910和A549移植瘤，只稍微抑制肿瘤生长。因此, AST-1306作用于过量表达ErbB2的肿瘤模型，效果比表达低水平ErbB2的肿瘤效果高很多。AST-1306耐药性很好。 Lapatinib作用于过量表达ErbB2的肿瘤模型，具有抗癌活性，但是按相同剂量及饲喂安排作用于SK-OV-3 移植瘤模型，AST-1306比Lapatinib 效果好。此外, AST-1306 口服处理FVB-2/Nneu模型，每天两次，持续3周，显著抑制肿瘤生长。处理11天后 ,肿瘤几乎完全消失。在药物处理期间，鼠体重降低小于20% 。[1] | |
|---|---|---|
| 动物实验 | Animal Models | 携带SK-OV-3移植瘤的裸鼠和SK-OV-3FVB-2/Nneu转基因鼠 |
| Dosages | 25 mg/kg, 50 mg/kg和100 mg/kg | |
| Administration | 口服处理,每天两次 | |
化学信息&溶解度
| 分子量 | 621.08 | 分子式 | C24H18ClFN4O2,C7H8O3S |
| CAS号 | 1050500-29-2 | SDF | Download Allitinib tosylate SDF |
| Smiles | CC1=CC=C(C=C1)S(=O)(=O)O.C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 124 mg/mL ( (199.65 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Allitinib tosylate | Allitinib tosylate supplier | purchase Allitinib tosylate | Allitinib tosylate cost | Allitinib tosylate manufacturer | order Allitinib tosylate | Allitinib tosylate distributor
